Study confirms biological mechanism responsible for latent HIV reservoirs; suggests strategies for a functional HIV cure.
For the first time scientists have identified how to halt kidney disease in a life-limiting genetic condition, which may pave the way for personalised treatment in the future.
How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomized trials, but is this really the only reliable way to evaluate treatment effectiveness, or could something be done differently? How can the effectiveness of a treatment method be evaluated in practice? Could some patients benefit from a treatment that does not cause a response in others? A new method developed by Finnish researchers now provides answers to these questions.
A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease. The paper was published today in the Journal of the American Medical Association Network Open.
The article highlights several conditions presenting with similar signs and symptoms to those of arthritis which may offer diagnostic confusion.
Results published today in JAMA Oncology suggest post-operative radiation and hormone therapy, before cancer recurrence, as a new prostate cancer treatment option for men with a Gleason Score of 9 or 10.
Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some cases. They have survived for longer without the disease progressing than the usual average time of less than five months, even though their cancer was advanced and had not responded to previous therapies. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
A 15-minute scan could help diagnose brain damage in babies up to two years earlier than current methods.
A combination of two drugs, which prompt the body's immune system to identify and kill cancer cells, is a safe treatment for patients with advanced non-small cell lung cancer and has shown some signs of efficacy. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
Early results from a phase I trial in a small group of patients with advanced cancer using two drugs (nivolumab and pixatimod) that stimulate the immune system report that patients with bowel cancer may benefit from the combination. The research is presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.